MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
| 1.92 | |
| 1.82 | |
| - | |
| 1.92 | |
| 1.82 | |
| 1.6232-63.9 | |
| 4 314 K | |
| 2 370 K | |
| 0 | |
| -5.1384 | |
| 2.692 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Support for cannabis legalization reached all-time highs in 2023, creating a long list of cannabis stocks to buy. For one, a new Gallup survey found that 70% of Americans believe cannabis should be l...
In this piece, we will take a look at the 12 most profitable pot stocks now. If you want to skip our overview of the pot and cannabis industry, then you can skip ahead to 5 Most Profitable Pot Stocks ...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
